Mayo Clinic | Strategic Alliance Partners

January 13, 2021

Sikander Ailawadhi, MD, discusses the emergence of T-cell engagers in multiple myeloma.

January 13, 2021

Yi Lin, MD, PhD, discusses CAR T-cell therapy–related toxicities in multiple myeloma.

January 13, 2021

Rafael Fonseca, MD, discusses the emergence of minimal residual disease in multiple myeloma.

January 08, 2021

Shaji K. Kumar, MD, discusses sequencing selinexor-based combinations in relapsed/refractory multiple myeloma.

January 08, 2021

Brexucabtagene autoleucel induced durable response in patients with relapsed/refractory mantle cell lymphoma, according to findings from the phase 2 ZUMA-2 trial, leading to an FDA approval for use in this patient population on July 24, 2020.

January 06, 2021

Tanios S. Bekaii-Saab, MD, FACP, discusses incorporating potential mechanisms of resistance into treatment selection in hepatocellular carcinoma.

January 05, 2021

Sikander Ailawadhi, MD, discusses the integration of selinexor into the treatment landscape of relapsed/refractory multiple myeloma.

January 05, 2021

Yi Lin, MD, PhD, discusses the characteristics of patients who were included in the CRB-401 study examining the CAR T-cell product idecabtagene vicleucel in multiple myeloma.

December 30, 2020

Alex A. Adjei, MD, PhD, discusses frontline treatment options for patients with advanced non–small cell lung cancer, as well as some of the nuances of selecting the optimal therapy.

December 21, 2020

Matthew P. Goetz, MD, discusses ongoing research in the setting of ESR1-mutant, ER–positive, HER2-negative metastatic breast cancer.

December 20, 2020

Rami Manochakian, MD, discusses the role of osimertinib in patients with EGFR-mutated NSCLC, strategies for treatment following progression on the third-generation TKI, and ongoing research efforts to further improve care.

December 18, 2020

Javier L. Munoz, MD, discusses the nuances of choosing treatment options for patients with CLL in the frontline and relapsed/refractory settings, as well as novel therapeutic strategies on the horizon.

December 09, 2020

December 9, 2020 — The BCMA-targeted antibody-drug conjugate MEDI2228 showed promising clinical efficacy in patients with relapsed/refractory multiple myeloma, with triple-refractory disease experiencing maintained responses.

November 19, 2020

Tanios S. Bekaii-Saab, MD, FACP, discusses improved sequencing strategies in hepatocellular carcinoma.

November 10, 2020

Daniel H. Ahn, DO, discusses the role of checkpoint inhibitor therapy in patients with microsatellite instability–high colorectal cancer who harbor an NTRK fusion.

November 04, 2020

Tanios S. Bekaii-Saab, MD, FACP, discusses the future of telemedicine in colorectal cancer.

October 30, 2020

Daniel H. Ahn, DO, discusses the identification of NTRK alterations in colorectal cancer.

October 27, 2020

Daniel H. Ahn, DO, discusses the significance of the phase 3 KEYNOTE-177 trial in patients with microsatellite instability–high metastatic colorectal cancer.

October 23, 2020

Daniel H. Ahn, DO, discusses the evolution of targetable alterations in colorectal cancer.

October 21, 2020

Thorvardur Halfdanarson, MD, discusses the evolving role of immunotherapy in colorectal cancer.